Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo

被引：0
|
作者：
Kirsten Dettmar
Isabell Seitz-Merwald
Carsten Lindemann
Petra Schroeder
Diane Seimetz
Judith Atz
机构：
[1] Fresenius Biotech GmbH,
[2] EUFETS GmbH,undefined
来源：
Clinical and Translational Oncology | 2012年 / 14卷
关键词：
Catumaxomab; Trifunctional antibody; T lymphocyte; Endothelium; Adhesion; Redistributi;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：376 / 381
页数：5
相关论文
共 50 条
  • [31] Altered T lymphocyte migration in intestine by anti-CD3 stimulation
    Fujimori, H
    Miura, S
    Koseki, S
    Hokari, R
    Tsuzuki, Y
    Higuchi, H
    Serizawa, H
    Hachimura, S
    Kaminogawa, S
    Ishii, H
    JOURNAL OF VASCULAR RESEARCH, 1998, 35 : 48 - 48
  • [32] Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody:: A phase I/II study
    Burges, Alexander
    Wimberger, Pauline
    Kuemper, Carolin
    Gorbounova, Vera
    Sommer, Harald
    Schmalfeldt, Barbara
    Pfisterer, Jacobus
    Lichinitser, Michail
    Makhson, Anatoliy
    Moiseyenko, Vladimir
    Lahr, Angelika
    Schulze, Elisabeth
    Jaeger, Michael
    Stroehlein, Michael A.
    Heiss, Markus Maria
    Gottwald, Thomas
    Lindhofer, Horst
    Kimmig, Rainer
    CLINICAL CANCER RESEARCH, 2007, 13 (13) : 3899 - 3905
  • [33] Altered T lymphocyte migration in intestine by anti-CD3 stimulation
    Fujimori, H
    Miura, S
    Koseki, S
    Hokari, R
    Higuchi, H
    Tsuzuki, Y
    Serizawa, H
    Hachimura, S
    Kaminogawa, S
    Ishii, H
    20TH EUROPEAN CONFERENCE ON MICROCIRCULATION, 1998, : 325 - 328
  • [34] Peritoneal carcinomatosis immunotherapy with the trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab in patients with colon, gastric, or pancreatic cancer: Long-term results after a 2-year follow-up
    Stroehlein, M.
    Lordick, F.
    Ruettinger, D.
    Schemanski, O.
    Jaeger, M.
    Lindhofer, H.
    Hennig, M.
    Lahr, A.
    Heiss, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Interim results of a phase I study of M701, a recombinant anti-EpCAM and anti-CD3 bispecific antibody in EpCAM-positive cancer patients with malignant ascites
    Xu, J.
    Zhao, C.
    Jia, Y.
    Wang, S.
    Ma, X.
    Wang, T.
    Huang, S.
    Pei, M.
    Wang, X.
    Zhou, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S603 - S603
  • [36] Induction of anti-tumor immunity by concomitant cell therapy and trifunctional bispecific antibody anti-(CD3 x Anti-EpCAM)
    Slavin, Shimon
    Lindhofer, Horst
    Yacovlev, Elena
    Gelfand, Yael
    Morecki, Shoshana
    JOURNAL OF IMMUNOTHERAPY, 2006, 29 (06) : 676 - 676
  • [37] Randomized, multicenter, two-dose level, open-label, phase IIA study with theintraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EPCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients
    Burges, A.
    Pfisterer, J.
    Wimberger, P.
    Kurzeder, C.
    du Bois, A.
    Sehouli, J.
    Loibl, S.
    Burchardi, N.
    Vergote, I.
    Wagner, U.
    ONKOLOGIE, 2008, 31 : 102 - 102
  • [38] Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients
    Belau, A.
    Pfisterer, J.
    Wimberger, P.
    Kurzeder, C.
    Du Bois, A.
    Sehouli, J.
    Loibl, S.
    Burchardi, N.
    Vergote, I.
    Wagner, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients
    Loibl, S.
    Pfisterer, J.
    Wimberger, P.
    Kurzeder, C.
    Du Bois, A.
    Sehouli, J.
    Belau, A.
    Burchardi, N.
    Vergote, I.
    Wagner, U.
    EJC SUPPLEMENTS, 2007, 5 (04): : 312 - 312
  • [40] Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer
    Katzenwadel, A
    Schleer, H
    Gierschner, D
    Wetterauer, U
    Elsässer-Beile, U
    ANTICANCER RESEARCH, 2000, 20 (3A) : 1551 - 1555
12345